SCHEDULE 13D/A: Hillhouse Affiliates Reduce BeiGene Stake Through Significant ADS Sale
Beneficial Ownership Amendment
HHLR Advisors and Hillhouse Investment Management, affiliates under common control, have reduced their beneficial ownership in BeiGene, Ltd. to 6.7% following the sale of 2.48 million American Depositary Shares.
Summary
- This document is Amendment No. 6 to a Schedule 13D filing, updating the beneficial ownership of BeiGene, Ltd. by HHLR Advisors, Ltd. and Hillhouse Investment Management, Ltd.
- The reporting persons, HHLR Advisors, Ltd. and Hillhouse Investment Management, Ltd., are under common control and share policies, personnel, and resources.
- As of March 3, 2025, the aggregate beneficial ownership by the reporting persons is 92,805,741 Ordinary Shares, representing 6.7% of BeiGene, Ltd.'s outstanding Ordinary Shares.
- This percentage is calculated based on 1,393,867,704 Ordinary Shares outstanding as of February 20, 2025.
- On March 3, 2025, HHLR Fund, managed by HHLR Advisors, sold 2,480,000 American Depositary Shares (ADSs) of BeiGene, Ltd. in a block trade with Goldman Sachs & Co. LLC.
- The sale price for the ADSs was $244.50 per ADS.
- Prior to the sale, HHLR Fund held 79,357,423 ordinary shares (including 290,100 ADSs), and a fund managed by HIM held 13,448,318 ordinary shares (including 1,034,306 ADSs).
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a major investor reducing their stake through a significant block sale, which can imply reduced confidence or a shift in investment strategy.
Negatives
- A significant block of 2,480,000 ADSs was sold by HHLR Fund, indicating a reduction in a major investor's stake in BeiGene, Ltd.
Risks
- The sale by a major institutional investor could be perceived negatively by the market, potentially leading to downward pressure on BeiGene's share price.
- Reduced confidence from a significant shareholder might influence other investors' sentiment.
Future Outlook
This document does not contain any forward-looking statements or guidance from BeiGene, Ltd. or the reporting persons regarding the company's future performance or strategic direction.
Industry Context
This filing details a specific transaction by a major institutional investor (HHLR/Hillhouse) reducing its stake in BeiGene, Ltd. It does not provide broader industry context or trends for the biotechnology or pharmaceutical sector.
Stakeholder Impact
- Shareholders: May experience negative sentiment and potential downward pressure on share price due to the large block sale by a significant investor.
Key Dates
| Date | Description |
|---|---|
| 2025-02-20 | Date as of which 1,393,867,704 Ordinary Shares were reported outstanding, used for percentage calculation. |
| 2025-03-03 | Date of the event requiring the filing of this statement; HHLR Fund sold 2,480,000 ADSs. |
Keywords
BeiGene, SEC filing, Schedule 13D, beneficial ownership, ADS sale, HHLR Advisors, Hillhouse Investment Management, institutional investor, shareholding, block trade
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.